UBS Group
CABA icon

UBS Group’s Cabaletta Bio CABA Stock Holding History

UBS Group’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.58M Buy
1,471,895
+865,231
+143% +$2.85M ﹤0.01% 4250
2026
Q1 		$1.63M Buy
606,664
+190,987
+46% +$530K ﹤0.01% 5157
2025
Q4 		$910K Buy
415,677
+10,557
+3% +$26.2K ﹤0.01% 5657
2025
Q3 		$948K Sell
405,120
-66,922
-14% -$115K ﹤0.01% 5619
2025
Q2 		$718K Sell
472,042
-18,158
-4% -$28.3K ﹤0.01% 5717
2025
Q1 		$679K Buy
490,200
+55,643
+13% +$119K ﹤0.01% 5602
2024
Q4 		$986K Buy
434,557
+411,783
+1,808% +$1.45M ﹤0.01% 5304
2024
Q3 		$107K Sell
22,774
-45,799
-67% -$265K ﹤0.01% 6308
2024
Q2 		$513K Sell
68,573
-140,903
-67% -$1.73M ﹤0.01% 4976
2024
Q1 		$3.57M Buy
209,476
+70,831
+51% +$1.52M ﹤0.01% 3336
2023
Q4 		$3.15M Buy
138,645
+103,662
+296% +$1.74M ﹤0.01% 3307
2023
Q3 		$532K Buy
34,983
+20,063
+134% +$274K ﹤0.01% 4598
2023
Q2 		$193K Buy
14,920
+13,300
+821% +$144K ﹤0.01% 5505
2023
Q1 		$13.4K Buy
1,620
+74
+5% +$693 ﹤0.01% 7398
2022
Q4 		$14.3K Sell
1,546
-48,454
-97% -$176K ﹤0.01% 8084
2022
Q3 		$33K Buy
+50,000
New +$60.2K ﹤0.01% 6756
2021
Q4 		– Sell
-964
Closed -$12K – 10275
2021
Q3 		$12K Buy
964
+741
+332% +$6.83K ﹤0.01% 7745
2021
Q2 		$2K Sell
223
-718
-76% -$7.05K ﹤0.01% 8928
2021
Q1 		$10K Sell
941
-996
-51% -$12.2K ﹤0.01% 7915
2020
Q4 		$24K Buy
1,937
+1,772
+1,074% +$23K ﹤0.01% 6800
2020
Q3 		$2K Sell
165
-4,384
-96% -$50.4K ﹤0.01% 7635
2020
Q2 		$51K Buy
4,549
+691
+18% +$5.29K ﹤0.01% 5834
2020
Q1 		$28K Sell
3,858
-4,184
-52% -$57.4K ﹤0.01% 6261
2019
Q4 		$112K Buy
+8,042
New +$95.3K ﹤0.01% 5947

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

UBS Group's CABA Position: Q2 2026 in Review

UBS Group increased its Cabaletta Bio (CABA) stake by 143% in Q2 2026, buying an estimated $2.85M and bringing the position to 1,471,895 shares worth $4.58M. The position accounts for ﹤0.01% of the portfolio, ranked #4250.

UBS Group first reported a position in CABA in Q4 2019 and has held it in 24 quarters since. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • UBS Group held 1,471,895 shares of Cabaletta Bio worth $4.58M as of Q2 2026.
  • UBS Group bought 865,231 Cabaletta Bio shares in Q2 2026, an estimated $2.85M.
  • Cabaletta Bio made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4250 holding.
  • UBS Group first reported a position in Cabaletta Bio in Q4 2019 and has held it in 24 quarters since.
  • 140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.